<p>High-throughput experiments, unidirectional fluid replacement, real-time process monitoring, and simultaneous drug sensitivity and toxicity tests are hard to achieve on most existing tumor organoid chips. Here, we developed a gravity-driven organoid perfusion (GDOP) platform facilitating scalable throughput and supporting drug sensitivity and toxicity assessment on organoids. The unidirectional perfusion capability and optimized operational parameters of the GDOP chip were validated through fluid dynamics simulations. Using this platform, we successfully established uniform on-chip triple-negative breast cancer (TNBC) organoids, with endpoint detection results aligning closely with clinical diagnosis. Throughout the drug treatment process, we monitored and then analyzed the morphological and grayscale changes of the organoids. The sensitivity and toxicity tests revealed the optimal concentration range for the 3 chemotherapeutic drugs. In addition, on-chip brain organoids were established, which lays a feasible foundation for future drug toxicity tests of complex organoids. The GDOP platform, combined with its integrated evaluation method, provides a powerful and reliable approach for advancing organoid-based researches.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

A compatible gravity-driven organoid perfusion (GDOP) platform for drug screening with sensitivity and toxicity process evaluation

  • Shun Wang,
  • Xiaoliang Zhang,
  • Houshi Ma,
  • Linlin Lu,
  • Huabin Jiang,
  • Yuqiao Bai,
  • Xiaoran Chang,
  • Jinxian Wang,
  • Tianhang Yang,
  • Gangyin Luo

摘要

High-throughput experiments, unidirectional fluid replacement, real-time process monitoring, and simultaneous drug sensitivity and toxicity tests are hard to achieve on most existing tumor organoid chips. Here, we developed a gravity-driven organoid perfusion (GDOP) platform facilitating scalable throughput and supporting drug sensitivity and toxicity assessment on organoids. The unidirectional perfusion capability and optimized operational parameters of the GDOP chip were validated through fluid dynamics simulations. Using this platform, we successfully established uniform on-chip triple-negative breast cancer (TNBC) organoids, with endpoint detection results aligning closely with clinical diagnosis. Throughout the drug treatment process, we monitored and then analyzed the morphological and grayscale changes of the organoids. The sensitivity and toxicity tests revealed the optimal concentration range for the 3 chemotherapeutic drugs. In addition, on-chip brain organoids were established, which lays a feasible foundation for future drug toxicity tests of complex organoids. The GDOP platform, combined with its integrated evaluation method, provides a powerful and reliable approach for advancing organoid-based researches.